MONOCLONAL-ANTIBODY THERAPY IN LANGERHANS CELL HISTIOCYTOSIS - FEASIBLE AND REASONABLE

被引：0
|
作者：
KELLY, KM
PRITCHARD, J
机构：
[1] UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104
[2] HOSP SICK CHILDREN,DEPT HAEMATOL ONCOL,LONDON WC1N 3JH,ENGLAND
来源：
BRITISH JOURNAL OF CANCER | 1994年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Many recent studies have demonstrated the range of disorders in which monoclonal antibodies have a clinical role. The monoclonal antibody NA1/34, directed against a surface antigen present on lesional cells ('LCH cells'), has been found to localise in vivo to sites of disease. This review explores the possible applications and limitations of monoclonal antibody based-therapy in Langerhans cell histiocytosis.
引用
收藏
页码：S54 / S55
页数：2
相关论文
共 50 条
  • [41] Expression of the monoclonal antibody HECA-452 defined E-selectin ligands in Langerhans cell histiocytosis
    Simonitsch, I
    Kopp, CW
    Mosberger, I
    VolcPlatzer, B
    Radaszkiewicz, T
    VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 1996, 427 (05): : 477 - 481
  • [42] A human anti-CD1a monoclonal antibody for targeted immunotherapy in Langerhans Cell Histiocytosis and hematologic malignancies
    Bechan, G
    Lee, DW
    Egeler, RM
    Arceci, RJ
    BLOOD, 2005, 106 (11) : 284B - 284B
  • [43] Langerhans cell and non Langerhans cell histiocytosis
    Stéphan, JL
    ARCHIVES DE PEDIATRIE, 2002, 9 (09): : 934 - 941
  • [44] Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis
    Okamoto, Takeshi
    Murata, Yoji
    Hasegawa, Daiichiro
    Yoshida, Makiko
    Tanaka, Daisuke
    Ueda, Takashi
    Hazama, Daisuke
    Oduori, Okechi S.
    Komori, Satomi
    Takai, Tomoko
    Saito, Yasuyuki
    Kotani, Takenori
    Kosaka, Yoshiyuki
    Maniwa, Yoshimasa
    Matozaki, Takashi
    CANCER SCIENCE, 2023, 114 (05) : 1871 - 1881
  • [45] INTERLEUKIN-2 THERAPY OF LANGERHANS CELL HISTIOCYTOSIS
    HIROSE, M
    SAITO, S
    YOSHIMOTO, T
    KURODA, Y
    ACTA PAEDIATRICA, 1995, 84 (10) : 1204 - 1206
  • [46] Hydroxyurea: a new old therapy for Langerhans cell histiocytosis
    Zinn, Daniel J.
    Grimes, Amanda B.
    Lin, Howard
    Eckstein, Olive
    Allen, Carl E.
    McClain, Kenneth L.
    BLOOD, 2016, 128 (20) : 2462 - 2465
  • [47] RADIATION-THERAPY IN THE MANAGEMENT OF LANGERHANS CELL HISTIOCYTOSIS
    SELCH, MT
    PARKER, RG
    MEDICAL AND PEDIATRIC ONCOLOGY, 1990, 18 (02): : 97 - 102
  • [48] Hypercalcemia in Langerhans cell histiocytosis: Is it therapy-related?
    Jubinsky, PT
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (02) : 176 - 179
  • [49] Hydroxyurea Therapy for Pediatric Relapsed Langerhans cell Histiocytosis
    Shimizu, Soichiro
    Sakamoto, Kenichi
    Shioda, Yoko
    Terashima, Keita
    Matsumoto, Kimikazu
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S22 - S23
  • [50] Cladribine therapy in adults with advanced Langerhans cell histiocytosis
    Schini, Marian
    Makras, Polyzois
    Kanakis, George
    Voulgarelis, Michael
    Kaltsas, Gregory
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1541 - 1543
12345